Faculty

Paolo F Caimi

MD

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

Professor of Medicine

Cleveland Clinic Cancer Center, Cleveland, Ohio

Associate BMT and CT Director for Cellular Therapy

Case Comprehensive Cancer Center, Cleveland, Ohio

Medical Director, Clinical Research Office

Faculty

Marc S Hoffmann

MD

University of Kansas Cancer Center, Kansas City, Kansas

Director, Lymphoma Program, Associate Professor, Division of Hematologic Malignancies and Cellular Therapeutics

Faculty

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Faculty

Sonali M Smith

MD

The University of Chicago, Chicago, Illinois

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology/Oncology, Co-Leader, Cancer Service Line

Additional faculty to be announced.

Join us on Friday, December 11^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

MODULE 1: Clinical Utility of CD19-Directed Monoclonal Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

MODULE 2: Optimal Use of CD19-Directed Antibody-Drug Conjugates for Relapsed/Refractory DLBCL and FL

MODULE 3: Current and Future Role of Bruton Tyrosine Kinase Inhibition in the Management of NHL

MODULE 4: Role of Bcl-2 Inhibitors in the Management of Mantle Cell Lymphoma

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma.

Learning Objectives
At the conclusion of this activity, participants should be able to

• Understand published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), and apply this information in patient-education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with relapsed/refractory (R/R) DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for patients with mantle cell lymphoma (MCL), FL and DLBCL, and determine the utility of these agents in current and future clinical management.
• Assess the scientific basis for and available research findings with Bcl-2 inhibitors for patients with R/R MCL, and consider the current role of this novel therapeutic strategy.
• Review the mechanism of action and unique characteristics of cereblon E3 ligase modulators under development for FL and DLBCL, and appreciate available research findings with and ongoing studies evaluating the potential role of these novel agents.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing clinical trial opportunities with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Caimi — Advisory Committees: AbbVie Inc, Autolus, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Novartis, Recordati; Consulting Agreements: Bristol Myers Squibb; Contracted Research: ADC Therapeutics, Genmab US Inc, Incyte Corporation, Iovance Biotherapeutics, Recordati; Data and Safety Monitoring Boards/Committees: ADC Therapeutics; Stock OPTIONS — Private Companies: Abcon Therapeutics. Dr Hoffmann — Advisory Committees: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Novartis; Consulting Agreements: AbbVie Inc; Data and Safety Monitoring Boards/ Committees: Novartis. Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Lilly, Octapharma, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Acrotech Biopharma, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Nurix Therapeutics Inc, PeproMene Bio Inc. Additional faculty to be announced.

MODERATOR
Dr Smith — Advisory Committees: Genentech, a member of the Roche Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group; Contracted Research: Ipsen Biopharmaceuticals Inc. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb and Incyte Corporation.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Wednesday, September 2, 2026
5:00 PM – 6:30 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Diffuse Large B-Cell Lymphoma 
• Follicular Lymphoma and Mantle Cell Lymphoma  
• Chronic Lymphocytic Leukemia 

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies for newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).  
• Appraise the biological rationale for, available research findings with and current clinical role of antibody-drug conjugates for R/R DLBCL.  
• Evaluate the mechanism of action of and available clinical trial findings with bispecific T-cell engaging antibodies alone and in combination with other agents for FL, DLBCL and other forms of lymphoma.  
• Appreciate the biological rationale for, available data with and current clinical role of covalent and noncovalent Bruton tyrosine kinase (BTK) and Bcl-2 inhibitors for mantle cell lymphoma.  
• Recognize the prognostic and clinical significance of various biomarkers in chronic lymphocytic leukemia (CLL), such as del(17p), TP53 mutations and IGHV gene rearrangements, and use this information to individualize the selection of systemic therapy for patients with newly diagnosed disease. 
• Review the similarities and differences between covalent and noncovalent BTK inhibitors, and assess the implications for the efficacy and tolerability of these agents.  
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL.  
• Appreciate the scientific rationale for the investigation of covalent and noncovalent BTK inhibitors in combination with Bcl-2 inhibition, and review recently presented data with this strategy for newly diagnosed and R/R CLL.  
• Recall new data with agents and strategies currently under investigation for CLL and various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients. 

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Lilly, Octapharma, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Acrotech Biopharma, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Nurix Therapeutics Inc, PeproMene Bio Inc. Dr Sharman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne. Dr Siddiqi —  Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Pfizer Inc; Contracted Research: Bristol Myers Squibb.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genmab US Inc and Lilly.

This event has passed.

Faculty

Faculty

Christopher Flowers

MD, MS, FASCO

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Faculty

Matthew Lunning

DO

University of Nebraska Medical Center, Omaha, Nebraska

Professor, Chief of Hematology, Interim, Medical Director, Gene and Cellular Therapy, Assistant Vice Chancellor for Clinical Research, Fred and Pamela Buffett Cancer Center

Faculty

Sonali M Smith

MD

The University of Chicago, Chicago, Illinois

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology/Oncology, Co-Leader, Cancer Service Line

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

• Key factors in the selection of initial therapy for patients with DLBCL
• Extended follow-up from the Phase III POLARIX trial comparing polatuzumab vedotin with rituximab/cyclophosphamide/doxorubicin/prednisone (R-CHP) to R-CHOP for patients with previously untreated DLBCL; clinical activity observed with polatuzumab vedotin/R-CHP in various patient subsets
• Appropriate selection of patients to receive polatuzumab vedotin as a component of up-front therapy for DLBCL
• Efficacy and safety findings from the Phase III POLARGO study of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin for patients with R/R DLBCL; potential role of this regimen
• Available results, including those from the Phase III SUNMO trial, with polatuzumab vedotin combined with bispecific antibodies for patients with R/R DLBCL

MODULE 2: Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL)

• Extended follow-up from the Phase II L-MIND study supporting the use of tafasitamab/lenalidomide for patients with R/R DLBCL; optimal sequencing for individual patients
• Emerging positive findings from the Phase III frontMIND trial assessing tafasitamab and lenalidomide with R-CHOP versus R-CHOP alone as first-line therapy for DLBCL 
• Biological rationale for the evaluation of tafasitamab for FL
• Key efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide and rituximab (R2) for R/R FL or marginal zone lymphoma
• FDA approval of tafasitamab/R2 for patients with R/R FL; selection of appropriate candidates for this approach

MODULE 3: Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL

• Extended follow-up from the Phase II LOTIS-2 study supporting the use of loncastuximab tesirine for patients with R/R DLBCL
• Optimal sequencing of loncastuximab tesirine for individual patients with R/R DLBCL and ongoing studies designed to further define its role
• Initial results from the Phase Ib LOTIS-7 study of loncastuximab tesirine in combination with glofitamab for R/R DLBCL; implications for clinical practice and ongoing research
• Available data with loncastuximab tesirine for other subtypes of non-Hodgkin lymphoma (NHL)
• Recent NCCN Guidelines inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 4: Current and Future Role of Bruton Tyrosine Kinase (BTK) Inhibition in Therapy for Non-Hodgkin Lymphoma

• Key efficacy and safety outcomes with the addition of acalabrutinib to bendamustine/rituximab (BR) and maintenance rituximab for patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for transplant
• Recent FDA approval of acalabrutinib/BR as a front-line regimen for MCL; identification of optimal candidates for this strategy
• Published research findings with and ongoing studies of covalent BTK inhibitors as a component of up-front chemotherapy-free combination regimens for MCL
• Published efficacy and safety data from the Phase II ROSEWOOD study of zanubrutinib in combination with obinutuzumab for patients with FL who had received 2 or more previous systemic therapies; current clinical role
• Published clinical trial experience with BTK inhibitors for patients with newly diagnosed DLBCL
• Design, eligibility criteria and primary and secondary endpoints of the Phase III ESCALADE trial of acalabrutinib in combination with R-CHOP for patients aged 65 or younger with untreated non-GCB DLBCL; estimated completion date

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy would be appropriate.
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and apply this information in patient education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with relapsed/refractory (R/R) DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for patients with mantle cell lymphoma (MCL), FL and DLBCL, and determine the role of these agents in current and future clinical management.
• Assess emerging research findings with Bcl-2 inhibitors for patients with R/R MCL in order to prepare for the potential clinical availability of this novel treatment strategy.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Flowers — Consulting Agreements: BeOne, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group, Genmab US Inc, N-Power Medicine; Contracted Research: 4D Pharma PLC, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, BostonGene, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Guardant Health, Iovance Biotherapeutics, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Stock Options/Stock — Public Companies: Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, N-Power Medicine; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, National Cancer Institute, The V Foundation for Cancer Research. Dr Lunning — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Kite, A Gilead Company, Lyell Immunopharma, Pfizer Inc, Recordati. Dr Smith — Consulting Agreements: Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genmab US Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc.

MODERATOR
Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc. 

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Incyte Corporation.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Faculty

Faculty

Farrukh T Awan

MD

University of Texas Southwestern Medical Center, Dallas, Texas

Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program, Harold C Simmons Comprehensive Cancer Center

Faculty

Robin Klebig

MSN, APRN, CNP, AOCNP

Mayo Clinic, Rochester, Minnesota

Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology

Faculty

Mollie Moran

APRN-CNP, AOCNP

The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio

Nurse Practitioner

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting

MODULE 1: Current Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma (NHL)

• Design of bispecific antibodies to engage 2 disease targets with 1 molecule; potential therapeutic advantages over traditional monoclonal antibodies
• Scientific rationale for the selection of CD20 and CD3 as targets for bispecific antibodies in NHL; mechanism of antitumor activity
• Pharmacological similarities and differences among the various approved (eg, glofitamab, epcoritamab, mosunetuzumab) and investigational (eg, odronextamab) CD20 x CD3 bispecific antibodies for NHL; implications for efficacy, tolerability and ease of use
• Similarities and differences between bispecific antibodies and chimeric antigen receptor T-cell therapy
• FDA-approved indications for mosunetuzumab, glofitamab and epcoritamab; optimal selection and sequencing of bispecific antibodies for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

MODULE 2: Tolerability Concerns with Bispecific Antibodies for NHL

• Pathophysiology of the CRS and neurotoxicity observed with bispecific antibody therapy, including immune effector cell-associated neurotoxicity syndrome (ICANS)
• Comparative incidence and severity of CRS with bispecific antibodies available for various NHL subtypes
• Common signs and symptoms and typical course of CRS
• Clinical presentation of neurotoxicity/ICANS and common symptoms, such as delirium, dysphasia, lethargy, difficulty concentrating and confusion
• Guideline-endorsed approaches for monitoring, mitigation and management of CRS and neurotoxicity; role of corticosteroids, tocilizumab and other supportive care interventions
• Spectrum, frequency and severity of other common tolerability concerns, such as cytopenia, infections, fatigue, rash, musculoskeletal pain and gastrointestinal (GI) adverse events (AEs), with bispecific antibodies for patients with NHL

MODULE 3: Role of Polatuzumab Vedotin in Therapy for DLBCL

• Structural components of polatuzumab vedotin and mechanism of antitumor activity
• Extended follow-up with polatuzumab vedotin/R-CHP (rituximab, cyclophosphamide, doxorubicin and prednisone) for previously untreated DLBCL
• Current role of polatuzumab vedotin as a component of up-front therapy for DLBCL; appropriate selection of candidates for this strategy
• Efficacy and safety findings with polatuzumab vedotin in combination with chemoimmunotherapy (bendamustine/rituximab, rituximab/gemcitabine/oxaliplatin) or bispecific antibodies (mosunetuzumab) for patients with relapsed/refractory (R/R) DLBCL; current and potential role of these regimens

MODULE 4: Tolerability Considerations with Polatuzumab Vedotin

• Rates and severity of peripheral neuropathy with polatuzumab vedotin; appropriate use of dose adjustments and other management strategies
• Incidence of cytopenias and infections with polatuzumab vedotin-containing regimens; appropriate monitoring of complete blood counts (CBCs) during therapy
• Spectrum and incidence of GI AEs with polatuzumab vedotin-based therapy; strategies for management
• Differences, if any, in the tolerability of polatuzumab vedotin in the up-front versus the R/R setting; implications for AE monitoring and management

MODULE 5: Optimal Application of Loncastuximab Tesirine for Patients with DLBCL or FL

• Mechanism of action and structural makeup of the anti-CD19 antibody-drug conjugate loncastuximab tesirine
• Long-term findings with loncastuximab tesirine for R/R DLBCL; patient selection and optimal sequencing
• Available data with loncastuximab tesirine in combination with other therapies and for other NHL subtypes
• Recent NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 6: Tolerability Considerations with Loncastuximab Tesirine

• Incidence, severity and management of edema and effusions with loncastuximab tesirine
• Rates of myelosuppression and infections with loncastuximab tesirine; appropriate monitoring of CBCs during therapy
• Spectrum of cutaneous reactions documented with loncastuximab tesirine, such as photosensitivity reactions, rash and erythema; recommended strategies for mitigation and management
• Initial dosing and dose-modification strategies with loncastuximab tesirine; recommended premedications, such as dexamethasone and G-CSF, for some or all patients

MODULE 7: Current and Future Role of Covalent and Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitors in the Management of Chronic Lymphocytic Leukemia (CLL)

• Indications for initiating active therapy for patients with previously untreated CLL
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve and R/R CLL; application in current up-front decision-making
• Comparative antitumor activity of BTK inhibitors alone and in combination with anti-CD20 antibodies in the up-front setting; implications for therapy selection

MODULE 8: Tolerability of Covalent and Noncovalent BTK Inhibitors

• Incidence and severity of cardiac arrhythmias, including atrial fibrillation or flutter, documented with approved covalent BTK inhibitors
• Probability of other cardiovascular toxicities, such as stroke, hypertension and bruising or bleeding events, with covalent BTK inhibitor therapy
• Spectrum and frequency of clinically relevant noncardiovascular toxicities, including cytopenias, infections, headache, dermatologic symptoms, arthralgia/myalgia and GI events, with covalent BTK inhibitors
• Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving covalent BTK inhibitors
• Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
• Incidence and severity of cardiac arrhythmias and other cardiovascular and noncardiovascular toxicities documented with pirtobrutinib
• Appropriate monitoring for and management of treatment-related AEs in patients receiving pirtobrutinib
• Safety profile of pirtobrutinib in the front-line setting

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
• Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted antibody-drug conjugate (ADC) therapy would be appropriate.
• Appraise available research findings with and the current clinical role of CD19-targeted ADCs for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review data with and the current and potential role of this strategy for patients with newly diagnosed and R/R CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/NHLandCLL/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Klebig and Ms Moran have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.

MODERATOR — Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Lilly.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.